PROUD results published showing pre-exposure prophylaxis
effectively prevents HIV
10 September 2015
Results from the PROUD study, showing a daily pill can
effectively protect people from HIV infection, were published today
The Lancet. PROUD is the first study of the pre-exposure
prophylaxis approach to preventing HIV to be carried out in the UK.
The results show the approach could play a major role in reducing
the number of new infections among men who have sex with men.
Pre-exposure prophylaxis (PrEP) is a HIV
prevention strategy that involves HIV-negative people taking
antiretroviral drugs to reduce the risk of becoming infected if
they are exposed to the virus. The
PROUD study looked at whether offering daily PrEP to men who
have sex with men was an effective way to prevent HIV
infection. The results show that PrEP is highly protective,
reducing the risk of infection for this group by 86%.
24 February 2015
The PROUD study today reported that PrEP reduced the
risk of HIV infection by 86% for gay and other men who have sex
with men when delivered in sexual health clinics in
The PROUD study measured the effectiveness of
daily PrEP for gay and other men who have sex with men in
England. The results released at the Conference on
Retroviruses and Opportunistic Infections today indicate that PrEP
is highly protective for this group, reducing the risk of infection
by 86%. The researchers concluded that PrEP offers a major
opportunity to curb new HIV infections in men who have sex with men
in the UK.
The PROUD Study
Examining the impact on gay men of using Pre-Exposure
What is PrEP?
PrEP (Pre-Exposure Prophylaxis) is a new way to reduce
the risk of getting HIV. It involves HIV negative people taking a
daily tablet that contains drugs commonly used to treat
PROUD is a two-year study to recruit volunteers across England,
who will be placed at random into one of two groups. One group will
use PrEP from the start of the study, and the other group will
receive PrEP after 12 months.
Truvada (which contains tenofovir and emtricitabine, also called
FTC) is used in this study. Truvada is already widely used and any
side effects are usually mild.
Previous studies with gay men found that using PrEP almost
halved HIV infections – and there were even fewer infections
amongst men who took their pill every day.